Skip to main content

Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity

Author(s): Dannenfelser, Ruth; Nome, Marianne; Tahiri, Andliena; Ursini-Siegel, Josie; Vollan, Hans K M; et al

Download
To refer to this page use: http://arks.princeton.edu/ark:/88435/pr1gg2p
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDannenfelser, Ruth-
dc.contributor.authorNome, Marianne-
dc.contributor.authorTahiri, Andliena-
dc.contributor.authorUrsini-Siegel, Josie-
dc.contributor.authorVollan, Hans K M-
dc.contributor.authorHaakensen, Vilde D-
dc.contributor.authorHelland, Åslaug-
dc.contributor.authorNaume, Bjørn-
dc.contributor.authorCaldas, Carlos-
dc.contributor.authorBørresen-Dale, Anne-Lise-
dc.contributor.authorKristensen, Vessela N-
dc.contributor.authorTroyanskaya, Olga G-
dc.date.accessioned2021-10-08T19:48:57Z-
dc.date.available2021-10-08T19:48:57Z-
dc.date.issued2017en_US
dc.identifier.citationDannenfelser, Ruth, Marianne Nome, Andliena Tahiri, Josie Ursini-Siegel, Hans Kristian Moen Vollan, Vilde D. Haakensen, Åslaug Helland, Bjørn Naume, Carlos Caldas, Anne-Lise Børresen-Dale, Vessela N. Kristensen, and Olga G. Troyanskaya. "Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity." Oncotarget 8, no. 34 (2017): pp. 57121-57133. doi:10.18632/oncotarget.19078en_US
dc.identifier.issn1949-2553-
dc.identifier.urihttp://arks.princeton.edu/ark:/88435/pr1gg2p-
dc.description.abstractThe tumor microenvironment is now widely recognized for its role in tumor progression, treatment response, and clinical outcome. The intratumoral immunological landscape, in particular, has been shown to exert both pro-tumorigenic and anti-tumorigenic effects. Identifying immunologically active or silent tumors may be an important indication for administration of therapy, and detecting early infiltration patterns may uncover factors that contribute to early risk. Thus far, direct detailed studies of the cell composition of tumor infiltration have been limited; with some studies giving approximate quantifications using immunohistochemistry and other small studies obtaining detailed measurements by isolating cells from excised tumors and sorting them using flow cytometry. Herein we utilize a machine learning based approach to identify lymphocyte markers with which we can quantify the presence of B cells, cytotoxic T-lymphocytes, T-helper 1, and T-helper 2 cells in any gene expression data set and apply it to studies of breast tissue. By leveraging over 2,100 samples from existing large scale studies, we are able to find an inherent cell heterogeneity in clinically characterized immune infiltrates, a strong link between estrogen receptor activity and infiltration in normal and tumor tissues, changes with genomic complexity, and identify characteristic differences in lymphocyte expression among molecular groupings. With our extendable methodology for capturing cell type specific signal we systematically studied immune infiltration in breast cancer, finding an inverse correlation between beneficial lymphocyte infiltration and estrogen receptor activity in normal breast tissue and reduced infiltration in estrogen receptor negative tumors with high genomic complexity.en_US
dc.format.extent57121 - 57133en_US
dc.language.isoen_USen_US
dc.relation.ispartofOncotargeten_US
dc.rightsFinal published version. This is an open access article.en_US
dc.titleData-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexityen_US
dc.typeJournal Articleen_US
dc.identifier.doi10.18632/oncotarget.19078-
pu.type.symplectichttp://www.symplectic.co.uk/publications/atom-terms/1.0/journal-articleen_US

Files in This Item:
File Description SizeFormat 
ImmuneLarge.pdf12.82 MBAdobe PDFView/Download


Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.